# Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

> **NCT00103844** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 150 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Philadelphia-Positive Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00103844
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-08
- **Final completion:** 2008-03
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2010-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103844, "Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00103844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*